AUTHOR=Cui Yuexin , Sun Jiejie , Hao Wenyan , Chen Mengyu , Wang Yingzi , Xu Fenghua , Gao Chunsheng 

TITLE=Dual-Target Peptide-Modified Erythrocyte Membrane-Enveloped PLGA Nanoparticles for the Treatment of Glioma

JOURNAL=Frontiers in Oncology

VOLUME=10

YEAR=2020

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2020.563938

DOI=10.3389/fonc.2020.563938

ISSN=2234-943X

ABSTRACT=<p>Penetration of the blood–brain barrier (BBB) and the blood–brain tumor barrier (BBTB) remains a significant challenge for the delivery of drugs in the treatment of glioma. Therefore, the development of targeted preparations with the ability to penetrate the BBB and BBTB, and target gliomas, is an important approach if we are to improve the efficacy of glioma treatment. In the current study, an active targeting preparation based on PLGA nanoparticles coated with erythrocyte membranes (RBCNPs) and dual-modified with <sup>D</sup>WSW and NGR peptide ligands (<sup>D</sup>WSW/NGR-RBCNPs). Euphorbia factor L1 (EFL1) extracted from euphorbiae semen was used as the model drug. The final nanoparticles were characterized by <italic>in vivo</italic> and <italic>in vitro</italic> tests. <italic>In vitro</italic> results showed that EFL1-loaded <sup>D</sup>WSW/NGR-RBCNPs were taken up by cells and had the ability to penetrate the BBB and BBTB and produce cytotoxic effects. Furthermore, <italic>in vivo</italic> studies in mice showed that when injected intravenously, these specialized NPs could enter the brain, target tumor tissue, and significantly extend life span. The results showed that dual-targeting EFL1-loaded <sup>D</sup>WSW/NGR-RBCNPs have significant potential as a nanotherapeutic tool for the treatment of brain glioma.</p>